Clinical trial · Observational
Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors
NCT05733091CI-TRIAL-00108944recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To learn about the symptoms and changes our patients experience while receiving treatment for sinonasal or nasopharyngeal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Standard of Care | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN)
- timeFrame
- through study completion; an average of 1 year
- description
- MD Anderson Symptom Inventory Head and Neck Module (MDASI-HN) is a disease specific PRO instrument validated for patients with head and neck cancer. It is the most commonly utilized instrument in the head and neck cancer population, of which sinonasal and nasopharyngeal tumors are disease subsites. Score scale from 0 (symptom has been present) to 10 (the symptom was as bad as you can imagine it could be)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. Previously untreated patients with or suspected to have sinonasal malignancy or nasopharyngeal malignancy diagnosis based on either outside pathology report or MD Anderson pathology report. 2. Age ≥ 18 years 3. Plan to obtain the majority of treatment at MDACC including surgery and radiotherapy 4. Ability to understand and willingness to sign written informed consent Exclusion criteria: 1. History of the previous solid or liquid malignancies, apart from skin cancers treated with local therapy. 2. Existing neurocognitive impairment that is not the result of sinonasal and nasopharyngeal cancers or is treatment. 3. Previous treatment for sinonasal or nasopharyngeal carcinomas, apart from biopsy.
References
Publications (0)
Data not yet available
No reference posted for this study.